Search results
Showing 1591 to 1605 of 8933 results
Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)
Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over.
NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not provide an adequate evidence submission for committee decision-making.
Show all sections
Sections for TA972
NICE is unable to make a recommendation on concizumab (Alhemo) for treating haemophilia A or B in people 12 years and over with factor inhibitors. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1124
NICE is unable to make a recommendation on pembrolizumab (Keytruda) with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma in adults. This is because Merck Sharpe & Dohme will not be proceeding with the evidence submission for the appraisal.
Show all sections
Sections for TA1125
Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.
Secukinumab for treating active ankylosing spondylitis (TA407)
Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis.
Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)
Evidence-based recommendations on selective internal radiation therapies SIR-Spheres (Sirtex), TheraSphere (BTG) and QuiremSphere (Quirem Medical) for treating hepatocellular carcinoma in adults.
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer in adults.
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer (TA1130)
Evidence-based recommendations on talazoparib (Talzenna) with enzalutamide (Xtandi) for untreated hormone-relapsed metastatic prostate cancer.
Targeted-release budesonide for treating primary IgA nephropathy (TA1128)
Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Obinutuzumab with mycophenolate mofetil for treating lupus nephritis (TA1131)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with mycophenolate mofetil for treating lupus nephritis in adults.
Evidence-based recommendations on tirzepatide (Mounjaro) for managing overweight and obesity in adults.
NICE is unable to make a recommendation on ruxolitinib (Jakavi) for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1132
Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.